Short revision bullets only, not a replacement for the full lesson sections below.
Toggle for a short revision list before a mock or question block.
Pathophysiology
Clinical meaning
the clinician must master advanced heart failure classification, guideline-directed medical therapy (GDMT), and ECG interpretation at a diagnostic level. Understanding the molecular pharmacology and pathophysiological rationale behind each therapeutic intervention enables evidence-based prescribing decisions that directly impact patient survival and quality of life.
Heart Failure Classification and Staging requires understanding both the structural progression and functional impact of cardiac disease. The ACC/AHA staging system reflects the irreversible continuum of heart failure: Stage A identifies patients at risk due to hypertension, diabetes, obesity, coronary artery disease, or cardiotoxic drug exposure who have no structural heart disease yet but whose risk factors are initiating subclinical myocardial damage through oxidative stress, chronic inflammation, and neurohormonal activation. Stage B represents structural heart disease without symptoms, where pathological remodeling is occurring at the cellular level through myocyte hypertrophy, interstitial fibrosis from activated cardiac fibroblasts depositing collagen types I and III, and early apoptotic cell loss, but compensatory mechanisms maintain adequate cardiac output at rest. Stage C marks the transition to symptomatic heart failure where compensatory mechanisms have been overwhelmed and the neurohormonal activation (RAAS, sympathetic nervous system, endothelin, vasopressin) that initially maintained perfusion now drives disease progression through further myocyte death, fibrosis, and adverse remodeling. Stage D represents refractory heart failure requiring advanced therapies including left ventricular assist devices (LVADs), cardiac transplantation, or palliative care, where the myocardium has sustained irreversible damage beyond pharmacological rescue.
The NYHA Functional Classification provides a dynamic assessment that can change with treatment. Class I patients have no limitation of physical activity with ordinary activity not causing symptoms. Class II reflects mild limitation where patients are comfortable at rest but ordinary physical activity results in fatigue, dyspnea, or palpitations. Class III indicates marked limitation where less-than-ordinary activity causes symptoms, and Class IV patients experience symptoms at rest with inability to carry out any physical activity without discomfort. The distinction between Class II and III has important therapeutic implications, as ICD implantation for primary prevention is recommended only for patients with NYHA Class II-III symptoms and EF less than or equal to 35 percent despite optimal medical therapy.
Ejection Fraction Categories define distinct pathophysiological entities. Heart Failure with Reduced Ejection Fraction (HFrEF, EF 40 percent or less) represents systolic dysfunction where cardiomyocyte loss, reduced calcium cycling efficiency (downregulated SERCA2a, hyperphosphorylated ryanodine receptors causing diastolic calcium leak), and sarcomeric dysfunction impair the ventricle' ability to generate adequate contractile force. The reduced ejection fraction directly reflects diminished fractional shortening of the remaining functional sarcomeres. Heart Failure with Preserved Ejection Fraction (HFpEF, EF 50 percent or more) represents diastolic dysfunction where the primary abnormality is impaired ventricular relaxation and increased passive stiffness. At the cellular level, HFpEF involves titin isoform switching from the compliant N2BA isoform to the stiffer N2B isoform, titin hypophosphorylation reducing its compliance, cardiomyocyte hypertrophy with increased collagen cross-linking in the extracellular matrix, and coronary microvascular endothelial dysfunction that reduces nitric oxide bioavailability. This NO deficiency decreases cGMP-PKG signaling, which normally promotes titin phosphorylation and myocardial relaxation. HFpEF has no proven mortality-reducing therapies, though SGLT2 inhibitors showed benefit in the EMPEROR-Preserved trial, possibly through their effects on interstitial fluid mobilization, reduced inflammation, and improved endothelial function.
Guideline-Directed Medical Therapy (GDMT) for HFrEF is built on the Four Pillars, each targeting distinct pathological mechanisms. Pillar 1 involves RAAS Inhibition using ACE inhibitors, ARBs, or preferably the angiotensin receptor-neprilysin inhibitor (ARNI) sacubitril/valsartan. The RAAS pathway drives heart failure progression through multiple mechanisms: angiotensin II causes direct vasoconstriction (increasing afterload), stimulates aldosterone secretion (promoting sodium retention and potassium excretion), triggers myocardial fibrosis through TGF-beta activation, induces cardiomyocyte hypertrophy, and promotes oxidative stress through NADPH oxidase activation. ACE inhibitors block the conversion of angiotensin I to angiotensin II but also inhibit bradykinin degradation, which is responsible for their characteristic cough side effect but also contributes to their vasodilatory benefit. The ARNI sacubitril/valsartan provides dual neurohormonal modulation: sacubitril inhibits neprilysin, the enzyme that degrades natriuretic peptides (ANP, BNP, CNP), endogenous vasodilators that promote natriuresis, diuresis, and suppress RAAS activation and sympathetic tone. The PARADIGM-HF trial demonstrated a 20 percent reduction in cardiovascular death with ARNI compared to enalapril, establishing it as the preferred first-line RAAS inhibitor for HFrEF. Critically, ARNI cannot be given within 36 hours of an ACE inhibitor due to the risk of angioedema from excessive bradykinin accumulation.
Pillar 2 involves specific evidence-based beta-blockers: carvedilol, metoprolol succinate (extended-release), or bisoprolol. These three are the only beta-blockers with demonstrated mortality reduction in heart failure through large randomized controlled trials (COPERNICUS, MERIT-HF, and CIBIS-II respectively). The rationale for beta-blockade in heart failure targets the maladaptive chronic sympathetic activation that initially compensates for reduced cardiac output but progressively harms the myocardium. Sustained beta-1 adrenergic stimulation causes cardiomyocyte apoptosis through calcium overload and oxidative stress, promotes ventricular arrhythmias through increased automaticity and triggered activity, downregulates beta-1 receptors (reducing myocardial responsiveness to catecholamines), and increases myocardial oxygen demand. Beta-blockers reverse these processes by reducing heart rate (improving diastolic filling and coronary perfusion), decreasing myocardial oxygen demand, preventing catecholamine-mediated apoptosis, and allowing beta-receptor re-sensitization. The start low and go slow principle reflects the fact that beta-blockers initially reduce contractility (negative inotropy) before the long-term beneficial remodeling effects manifest over 2-3 months of therapy.
Pillar 3 involves Mineralocorticoid Receptor Antagonists (MRAs): spironolactone or eplerenone. Aldosterone promotes myocardial fibrosis through direct activation of mineralocorticoid receptors on cardiac fibroblasts, stimulating collagen synthesis and deposition. It also causes endothelial dysfunction, promotes vascular inflammation, and triggers potassium and magnesium wasting that predisposes to arrhythmias. The RALES trial demonstrated a 30 percent mortality reduction with spironolactone in severe heart failure. Eplerenone is more selective for the mineralocorticoid receptor with fewer anti-androgenic side effects (gynecomastia, menstrual irregularities). Potassium monitoring is critical: the combination of an ACE inhibitor or ARB with an MRA substantially increases hyperkalemia risk, particularly in patients with renal insufficiency (GFR less than 30) or baseline potassium above 5.0 mEq/L.
Pillar 4 involves SGLT2 Inhibitors (dapagliflozin or empagliflozin), representing the most significant advance in heart failure therapy in recent years. Originally developed as diabetes medications, these agents provide cardiovascular benefit through multiple mechanisms independent of glucose lowering: osmotic diuresis reduces intravascular volume and preload without activating the compensatory neurohormonal responses seen with loop diuretics, improved myocardial energetics through a metabolic substrate shift from fatty acid oxidation toward more oxygen-efficient ketone body utilization, direct anti-inflammatory effects through NLRP3 inflammasome inhibition, reduced myocardial fibrosis through decreased TGF-beta signaling, and potential improvement in cardiomyocyte calcium handling. The DAPA-HF trial (dapagliflozin) and EMPEROR-Reduced trial (empagliflozin) both demonstrated significant reductions in heart failure hospitalization and cardiovascular death regardless of diabetes status, leading to their inclusion as a mandatory pillar of GDMT.
Additional HFrEF therapies include hydralazine plus isosorbide dinitrate (the V-HeFT combination), which provides both preload reduction through venous dilation (nitrate) and afterload reduction through arteriolar dilation (hydralazine). This combination is particularly beneficial in self-identified Black patients based on the A-HeFT trial, which demonstrated a 43 percent mortality reduction in this population, likely related to the combination' ability to restore nitric oxide bioavailability in patients with increased oxidative stress and endothelial dysfunction. Ivabradine selectively inhibits the If funny current in the SA node, reducing heart rate without affecting blood pressure, contractility, or intracardiac conduction. It is indicated for patients in sinus rhythm with resting heart rate above 70 bpm despite maximally tolerated beta-blocker therapy, based on the SHIFT trial showing reduced heart failure hospitalizations.
Advanced ECG interpretation for the clinician requires understanding the cellular electrophysiology underlying each waveform component. The P wave represents atrial depolarization, initiated by the SA node and conducted through Bachmann bundle to the left atrium. P wave morphology changes in atrial enlargement: right atrial enlargement produces tall peaked P waves (P pulmonale, greater than 2.5 mm in lead II) from increased right atrial mass generating a larger depolarization vector, while left atrial enlargement produces wide bifid P waves (P mitrale, greater than 0.12 seconds) because delayed left atrial depolarization through the hypertrophied left atrial wall extends the total P wave duration. The PR interval (normal 0.12-0.20 seconds) represents AV nodal conduction delay, which is the physiological mechanism preventing ventricular activation before atrial contraction is complete. First-degree AV block (PR greater than 0.20 seconds) reflects prolonged AV nodal conduction from increased vagal tone, medications (beta-blockers, calcium channel blockers, digoxin), or intrinsic AV nodal disease. The QRS complex represents ventricular depolarization, normally completed within 0.12 seconds through the His-Purkinje system. Bundle branch blocks produce characteristic wide QRS patterns because ventricular activation must proceed through slower cell-to-cell myocardial conduction rather than the rapid specialized conduction system. Right bundle branch block (RBBB) shows a characteristic rsR-prime pattern in V1 because the right ventricle depolarizes late, producing a terminal rightward vector. Left bundle branch block (LBBB) shows a broad monophasic R wave in the lateral leads (I, aVL, V5-V6) because left ventricular depolarization occurs through slow myocardial conduction from right to left rather than through the left bundle branches.
ST segment and T wave abnormalities require systematic interpretation. ST elevation indicates transmural ischemia or infarction: in STEMI, complete coronary occlusion causes transmural injury current flowing from the epicardium toward the endocardium, producing ST elevation in leads facing the injured territory with reciprocal ST depression in opposite leads. ST depression indicates subendocardial ischemia, where the subendocardium (most vulnerable to ischemia due to its distance from epicardial coronary arteries and exposure to highest intramural pressure) is injured while the epicardium remains viable. The T wave represents ventricular repolarization: normally upright because repolarization proceeds from epicardium to endocardium (opposite to depolarization), producing a vector in the same direction as the QRS. Inverted T waves suggest ischemia, strain, or repolarization abnormalities. Hyperacute T waves (tall, broad, symmetric) are the earliest ECG sign of STEMI, appearing within minutes of coronary occlusion as potassium leaks from injured myocytes, creating localized hyperkalemia that accelerates repolarization in the ischemic zone.
The QT interval encompasses both ventricular depolarization and repolarization, measured from the beginning of the QRS complex to the end of the T wave. Because QT varies with heart rate, the corrected QT (QTc) is calculated using Bazett formula (QTc = QT / square root of RR interval). Normal QTc is less than 440 ms in males and less than 460 ms in females. Prolonged QTc increases the risk of torsades de pointes, a polymorphic ventricular tachycardia that can degenerate into ventricular fibrillation. The mechanism involves prolonged Phase 2 and Phase 3 of the action potential, creating a vulnerable window where early afterdepolarizations (EADs) can trigger re-entrant circuits. Numerous medications prolong QT, including Class IA and III antiarrhythmics (sotalol, amiodarone, procainamide), certain antibiotics (fluoroquinolones, azithromycin, erythromycin), antipsychotics (haloperidol, ziprasidone), and methadone. The clinician must evaluate QTc before prescribing these agents and avoid combinations of QT-prolonging drugs. Hypokalemia, hypomagnesemia, and hypocalcemia all potentiate QT prolongation and must be corrected to reduce arrhythmia risk.
Device therapy decision-making is a critical clinical competency. Implantable Cardioverter-Defibrillators (ICDs) are indicated for primary prevention in patients with EF 35 percent or less despite at least 3 months of optimal GDMT, with NYHA Class II-III symptoms. The cellular rationale is that severely reduced EF indicates extensive myocardial scar that creates the substrate for re-entrant ventricular tachycardia: heterogeneous conduction velocities through scar border zones allow wavefronts to circle back on themselves, sustaining lethal arrhythmias. Cardiac Resynchronization Therapy (CRT) adds biventricular pacing and is indicated for patients with EF 35 percent or less, NYHA Class II-IV symptoms, and QRS duration 150 ms or greater (particularly with LBBB morphology). The cellular basis for CRT lies in mechanical dyssynchrony: in LBBB, the septum contracts early while the lateral wall contracts late, creating paradoxical septal motion and reduced efficiency. CRT coordinates contraction timing, improving ejection fraction by 5-10 percent, reducing mitral regurgitation through improved papillary muscle alignment, and reversing adverse remodeling through more uniform wall stress distribution. The combination CRT-D device provides both resynchronization and defibrillation capability and is preferred in patients meeting criteria for both therapies.
Anticoagulation management in atrial fibrillation requires understanding the thrombogenic mechanisms. Atrial fibrillation creates stasis in the left atrial appendage due to loss of organized atrial contraction, activating the coagulation cascade through contact pathway activation on exposed subendothelial collagen and tissue factor expression by dysfunctional endothelial cells. The CHA2DS2-VASc score guides anticoagulation decisions, with each point reflecting an independent risk factor for thromboembolism. Scores of 2 or more in males and 3 or more in females strongly favor anticoagulation. Direct oral anticoagulants (DOACs) are preferred over warfarin for nonvalvular atrial fibrillation based on landmark trials (RE-LY, ROCKET-AF, ARISTOTLE, ENGAGE-AF) showing comparable or superior efficacy with significantly reduced intracranial hemorrhage risk. DOACs offer predictable pharmacokinetics through specific target inhibition: dabigatran directly inhibits thrombin (Factor IIa), while rivaroxaban, apixaban, and edoxaban directly inhibit Factor Xa. Unlike warfarin, DOACs do not require INR monitoring but do require dose adjustment for renal function because all DOACs have some degree of renal elimination. Dabigatran has the highest renal dependence (80 percent renal elimination) and is contraindicated when CrCl is less than 30 mL/min. Apixaban has the least renal dependence (27 percent) and can be used cautiously in advanced renal disease. The clinician must assess CHA2DS2-VASc score, bleeding risk (HAS-BLED score), renal function, drug interactions, and patient preference when selecting anticoagulation therapy.
Exam Focus
Diagnosis & workup
Diagnostics & workup:
- Order 12-lead ECG with systematic interpretation (rate, rhythm, axis, intervals, ST/T changes)
- Order echocardiography for structural and functional assessment (EF, wall motion, valves)
- Order cardiac biomarkers: troponin (MI), BNP/NT-proBNP (heart failure), D-dimer (PE/DVT)
- Order lipid panel with calculated ASCVD risk score
- Order stress testing (exercise or pharmacologic) for stable angina evaluation
- Order cardiac catheterization for acute coronary syndrome or high-risk findings
We didn’t match sample stems to this lesson in the bank yet. You can still run a topic-scoped drill with the same pathway filters—items load from your live FNP pool.
